Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 16/20 | 0.59 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22579749 | 0.88 | NT5E (0.61) | NT5EDNPH1P2RX3P2RX2 | |
| SCHEMBL23042806 | 0.82 | NT5E (0.52) | NT5EP2RX3 | |
| SCHEMBL21046396 | 0.82 | ADORA3 (0.52) | — | |
| SCHEMBL19859374 | 0.82 | ADORA3 (0.52) | — | |
| SCHEMBL22569892 | 0.81 | NT5E (0.59) | NT5E | |
| SCHEMBL22569939 | 0.81 | NT5E (0.59) | NT5E | |
| SCHEMBL23042839 | 0.80 | NT5E (0.57) | NT5EDNPH1 | |
| SCHEMBL23042841 | 0.79 | NT5E (0.54) | NT5EDNPH1 | |
| SCHEMBL23052739 | 0.79 | NT5E (0.49) | NT5EDNPH1P2RX3P2RX2 | |
| SCHEMBL22569921 | 0.79 | NT5E (0.65) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021040356-A1 | C-NUCLEOSIDES, C-NUCLEOTIDES AND THEIR ANALOGS, EQUIVALENTS AND PRODRUGS THEREOF FOR ECTONUCLEOTIDASE INHIBITION | KAINOS MEDICINE, INC. (KR) | 2021-03-04 | — | — | WO | claimed |
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| WO-2021040356-A1 | C-NUCLEOSIDES, C-NUCLEOTIDES AND THEIR ANALOGS, EQUIVALENTS AND PRODRUGS THEREOF FOR ECTONUCLEOTIDASE INHIBITION | KAINOS MEDICINE, INC. (KR) | 2021-03-04 | — | — | WO | disclosed |
| WO-2020211672-A1 | CD73 INHIBITORS | BIOARDIS LLC (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020210970-A1 | IMIDAZOTRIAZINE DERIVATIVES AS CD73 INHIBITORS | BIOARDIS LLC (US) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204539-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | NT5E 8/4885DNPH1 1274/4885P2RX3 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.